The European Medicines Company (EMA) has concluded a assessment of the weight reduction drug naltrexone/bupropion (Mysimba), which used to be triggered by issues about doable long-term cardiovascular risks. The scientific assessment of the EMA’s Committee for Medicinal Products for Human Use (CHMP) used to be that on hand data urged that the benefits of its authorized indication “proceed to outweigh …
Learn Extra
